Arbutus Biopharma

The company has no commercial products, so realized pricing power is absent. If a finite HBV functional cure is achieved, pricing power could be meaningful given high unmet need and the value of stopping lifelong NA therapy.

Yet competitive dynamics are tightening: GSK’s bepirovirsen advanced to Priority Review with BTD in 2026, likely setting early benchmarks on efficacy, safety, and payor value frameworks. Without Phase 2b/3 imdusiran data, latent pricing power remains hypothetical.